Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Menu
Sign in
Sign in

Gilead exercises option for three programmes of Arcus Biosciences

Gilead Sciences has exercised its options, under an agreement signed last year, to obtain exclusive ex-US rights to Arcus Biosciences’ three programmes.

The programmes in Arcus’ portfolio are anti-TIGIT molecules, domvanalimab and AB308, and etrumadenant and quemliclustat, a dual adenosine A2a/A2b receptor antagonist and a small molecule CD73 inhibitor, respectively.

As part of the option exercise, Arcus will receive a total of $725m from Gilead.

Gilead and Arcus will jointly develop and share international costs and profits and market the opted programmes in the US.

Furthermore, Gilead will have exclusive rights outside the US with Arcus entitled to receive tiered royalty payments.

In May last year, the companies collaborated to co-develop and co-market current and future cancer drug candidates in the latter’s pipeline.

The 2020 deal was amended with Gilead exercising its option for all three programmes.

Henceforth, Arcus may be expected to conduct at least half of the clinical trials in the future while the expenses will be split by the companies.

The royalty payments to be made by Gilead to Arcus on product sales outside of the US were lowered marginally.

Arcus will handle the discovery and the initial development of therapy candidates against two new research targets chosen by the companies.

In addition, Gilead will not make the $100m option continuation payment due next year.

Gilead Sciences chairman and CEO Daniel O’Day said: “Gilead is pursuing some of the most promising mechanisms of action in oncology today, with the aim of achieving better treatment outcomes for more patients.

“The addition of three mid to late-stage clinical programmes into our oncology pipeline significantly expands the number of transformational medicines we can potentially deliver to people with cancer while also enabling our pursuit of novel combinations.”

An Fc-silent anti-TIGIT antibody, Domvanalimab is currently being analysed in Phase II and Phase II clinical trials for non-small cell lung cancer with AB308, an Fc-enabled anti-TIGIT antibody in the Phase I clinical developmental stage.

Etrumadenant is being assessed in Phase I and Phase II trials for NSCLC, colon cancer as well as prostate cancer.

Currently, in the Phase I trial, quemliclustat is being analysed for the treatment of metastatic pancreatic ductal adenocarcinoma (PDAC).

November 23rd, 2021 

https://www.pharmaceutical-technology.com/

 



0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies